Coronary artery disease treatment in diabetics: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 50: Line 50:


==Anticipated Outcomes==
==Anticipated Outcomes==
Resolution of both [[symptomatic]] and [[asymptomatic]] [[ischemia].
Resolution of both [[symptomatic]] and [[asymptomatic]] [[ischemia]].


==Other Concerns==
==Other Concerns==

Revision as of 16:25, 3 August 2010

WikiDoc Resources for Coronary artery disease treatment in diabetics

Articles

Most recent articles on Coronary artery disease treatment in diabetics

Most cited articles on Coronary artery disease treatment in diabetics

Review articles on Coronary artery disease treatment in diabetics

Articles on Coronary artery disease treatment in diabetics in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Coronary artery disease treatment in diabetics

Images of Coronary artery disease treatment in diabetics

Photos of Coronary artery disease treatment in diabetics

Podcasts & MP3s on Coronary artery disease treatment in diabetics

Videos on Coronary artery disease treatment in diabetics

Evidence Based Medicine

Cochrane Collaboration on Coronary artery disease treatment in diabetics

Bandolier on Coronary artery disease treatment in diabetics

TRIP on Coronary artery disease treatment in diabetics

Clinical Trials

Ongoing Trials on Coronary artery disease treatment in diabetics at Clinical Trials.gov

Trial results on Coronary artery disease treatment in diabetics

Clinical Trials on Coronary artery disease treatment in diabetics at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Coronary artery disease treatment in diabetics

NICE Guidance on Coronary artery disease treatment in diabetics

NHS PRODIGY Guidance

FDA on Coronary artery disease treatment in diabetics

CDC on Coronary artery disease treatment in diabetics

Books

Books on Coronary artery disease treatment in diabetics

News

Coronary artery disease treatment in diabetics in the news

Be alerted to news on Coronary artery disease treatment in diabetics

News trends on Coronary artery disease treatment in diabetics

Commentary

Blogs on Coronary artery disease treatment in diabetics

Definitions

Definitions of Coronary artery disease treatment in diabetics

Patient Resources / Community

Patient resources on Coronary artery disease treatment in diabetics

Discussion groups on Coronary artery disease treatment in diabetics

Patient Handouts on Coronary artery disease treatment in diabetics

Directions to Hospitals Treating Coronary artery disease treatment in diabetics

Risk calculators and risk factors for Coronary artery disease treatment in diabetics

Healthcare Provider Resources

Symptoms of Coronary artery disease treatment in diabetics

Causes & Risk Factors for Coronary artery disease treatment in diabetics

Diagnostic studies for Coronary artery disease treatment in diabetics

Treatment of Coronary artery disease treatment in diabetics

Continuing Medical Education (CME)

CME Programs on Coronary artery disease treatment in diabetics

International

Coronary artery disease treatment in diabetics en Espanol

Coronary artery disease treatment in diabetics en Francais

Business

Coronary artery disease treatment in diabetics in the Marketplace

Patents on Coronary artery disease treatment in diabetics

Experimental / Informatics

List of terms related to Coronary artery disease treatment in diabetics

Cardiology Network

Discuss Coronary artery disease treatment in diabetics further in the WikiDoc Cardiology Network
Adult Congenital
Biomarkers
Cardiac Rehabilitation
Congestive Heart Failure
CT Angiography
Echocardiography
Electrophysiology
Cardiology General
Genetics
Health Economics
Hypertension
Interventional Cardiology
MRI
Nuclear Cardiology
Peripheral Arterial Disease
Prevention
Public Policy
Pulmonary Embolism
Stable Angina
Valvular Heart Disease
Vascular Medicine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Associate Editors-In-Chief: Felipe Chaparro, M.D.; David M. Leder, M.D.; Brian C. Bigelow, M.D.

Background

Patients with diabetes are more likely to have coronary artery disease (CAD) than non-diabetic patients. Furthermore, they are more likely to have multivessel disease, and they more commonly present with atypical anginal symptoms, or even silent ischemia. Diabetic patients with CAD have lower long-term survival rates than nondiabetic patients with CAD.

Goals of Treatment

The main goal of treating diabetic patients with CAD is to decrease long term rates of death. It is important to carefully select those patients who would benefit from revascularization, and then to determine whether PCI or CABG is the preferred strategy. Among patients who undergo revascularization therapy, the major goal is to prolong their event-free survival time.

Treatment Choices

Medical Therapy

Strategies that include aggressive risk factor modification such as glycemic control with a target HbA1C <7, LDL <100 mg/dl, blood pressure <130/80, smoking cessation, weight loss and regular exercise, showed no significant difference in the rates of death and major cardiovascular events compared to prompt revascularization at 5 years of surveillance for stable ischemic heart disease.

Advantages of Medical Therapy: Medical treatment is a non-invasive treatment option which has shown similar outcomes at 5 years of surveillance for diabetic patients with stable ischemic heart disease when compared to PCI and CABG.

Percutaneous Revascularization

Initial procedural success is similar in both patients with diabetes and those without; however, diabetic patients have higher rates of restenosis and lower rates of event-free survival than nondiabetic patients. This is thought to be secondary to progression of disease in untreated areas and restenosis in treated areas.

After bare metal stent (BMS) placement, diabetic patients are more likely to have a decrease in event-free survival at 1-year with an increase in both overall and cardiac mortality. These same findings were consistent in studies with longer follow-up periods where diabetic patients had a higher incidence of mortality and need for repeat revascularization.

Drug-eluting stents (DES) are now used preferentially over BMS in most patients because they are associated with marked reductions in the incidence of restenosis and target lesion revascularization. At 4-year follow-up in the TAXUS trial[1], treatment of diabetic patients with Paclitaxel-eluting stents (PES) compared with BMS was safe and effective, resulting in markedly lower rates of target lesion revascularization, with similar rates of death, myocardial infarction, and stent thrombosis. As showed in several trials, like SIRIUS[2] and SCORPIUS[3], diabetic patients treated with Sirolimus-eluting stents (SES) had better outcomes with a significantly lower rate of target lesion revascularization, decreased late luminal loss, and major adverse cardiac events compared to those treated with bare metal stents. A meta-analysis comparing the clinical efficacy of drug-eluting stents in diabetic patients concluded that the revascularization and major adverse cardiovascular events estimates are similar with both PES and SES.

Advantages of Percutaneous Revascularization: PCI is generally associated with less morbidity and mortality than CABG. Given the dramatically lower rates of restenosis with drug-eluting stents, this approach is good for patients with focal one or two vessel disease, as long as the proximal LAD or left main are not involved.

Surgical Revascularization

As with PCI, death, major adverse cardiac events, short and long-term outcomes tend to be worse in diabetic patients compared to nondiabetic patients. Outcomes with coronary artery bypass graft surgery (CABG) are generally better than those treated with PCI or medical management, especially for multivessel disease and if there is involvement of the left anterior descending artery and an internal mammary artery is used.

Advantages of Surgical Revascularization: While contemporary trials comparing revascularization with drug-eluting stents versus CABG in diabetic patients with multivessel disease are ongoing, the available data comparing PCI to CABG in this setting are in favor of CABG with regards to long term outcomes.

Making a Selection

In diabetic patients, intensive medical treatment should be considered if the patient has stable angina that is not significantly interfering with the quality of life or for whom the procedure is not indicated to prolong life.

PCI with placement of drug-eluting stent(s) should be considered if the patient has:

  • Single vessel disease
  • 2 vessel disease excluding the proximal LAD
  • Older patients with significant comorbidities
  • Prior CABG

CABG (especially if an IMA can be used) should be considered if the patient has:

  • 3 vessel disease
  • Significant left main coronary artery stenosis
  • 2 vessel disease with one of the lesions being a proximal left anterior descending (LAD) coronary artery lesion
  • Significant coronary artery disease and also requires surgery for a heart valve

Regardless of treatment choice, all patients should have aggressive risk factor modification as well (i.e. antihypertensives, lipid control, tobacco cessation, regular exercise and blood sugar control).

Anticipated Outcomes

Resolution of both symptomatic and asymptomatic ischemia.

Other Concerns

Certain situations demand additional considerations. If a patient had angina or ischemia despite optimal medical management, revascularization should be considered. Also, if a patient has angina after having CABG, PCI with placement of drug-eluting stent(s) should be considered. Furthermore, if a patient fails PCI, either through initial technical failure or repeated episodes of restenosis, they should be considered for CABG – especially if an IMA can be used.

References

  1. Grube E, Silber S, Hauptmann KE; et al. (2003). "TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions". Circulation. 107 (1): 38–42. PMID 12515740. Unknown parameter |month= ignored (help)
  2. Holmes DR, Leon MB, Moses JW; et al. (2004). "Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis". Circulation. 109 (5): 634–40. doi:10.1161/01.CIR.0000112572.57794.22. PMID 14769686. Unknown parameter |month= ignored (help)
  3. Baumgart D, Klauss V, Baer F; et al. (2007). "One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients". J. Am. Coll. Cardiol. 50 (17): 1627–34. doi:10.1016/j.jacc.2007.07.035. PMID 17950142. Unknown parameter |month= ignored (help)

Template:SIB

Template:WikiDoc Sources Template:Mdr